MedPath

Evaluation of alternative bacteriological measures of response to therapy during the initial 16-weeks of MDR-TB (drug resistant tuberculosis) treatment

Not Applicable
Conditions
Alternative measures of response to MDR-TB (drug-resistant tuberculosis) therapy
Infections and Infestations
Registration Number
ISRCTN45714844
Lead Sponsor
Makerere University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
All
Target Recruitment
59
Inclusion Criteria

1. Adults >18 years of age
2. Have a productive cough
3. Sputum specimens that are positive for acid fast bacilli by microscopy (1+ to 3+, smear-positive)
4. Have been classified as MDR TB

Exclusion Criteria

1. Prisoners
2. Subjects <18 years of age
3. Patients who are unable to provide =3mL of sputum specimen for testing
4. Patients on anti-TB treatment

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sputum bacterial load burden, measured using Culture colony forming units (CFUs) as a reference standard, with MGIT time to positivity, Xpert PMA, FDA, Smear Microscopy, and TB-MBLA measured at weeks 0, 2, 4, 6, 8, 12 and 16
Secondary Outcome Measures
NameTimeMethod
<br> 1. Patient clinical characteristics will be collected using a detailed data collection tool at baseline (week 0)<br> 2. Baseline resistance profiles will be collected from the existing patient records at the clinic and tested using phenotypic drug susceptibility testing (DST) whenever possible<br> 3. Adherence measured using available clinical data and as collected by the study nurse during MDR-TB treatment<br> 4. HIV-status will be collected as documented in the clinic patient records at baseline<br>
© Copyright 2025. All Rights Reserved by MedPath